JP2022533368A5 - - Google Patents
Info
- Publication number
- JP2022533368A5 JP2022533368A5 JP2021568537A JP2021568537A JP2022533368A5 JP 2022533368 A5 JP2022533368 A5 JP 2022533368A5 JP 2021568537 A JP2021568537 A JP 2021568537A JP 2021568537 A JP2021568537 A JP 2021568537A JP 2022533368 A5 JP2022533368 A5 JP 2022533368A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- compound
- composition according
- administered
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962849185P | 2019-05-17 | 2019-05-17 | |
| US62/849,185 | 2019-05-17 | ||
| PCT/US2020/033232 WO2020236636A1 (en) | 2019-05-17 | 2020-05-15 | Methods of treating a mk2-mediated disorder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022533368A JP2022533368A (ja) | 2022-07-22 |
| JP2022533368A5 true JP2022533368A5 (https=) | 2023-05-18 |
Family
ID=73459478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021568537A Pending JP2022533368A (ja) | 2019-05-17 | 2020-05-15 | Ｍｋ２媒介性障害の治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220251105A1 (https=) |
| EP (1) | EP3969456A4 (https=) |
| JP (1) | JP2022533368A (https=) |
| KR (1) | KR20220041042A (https=) |
| CN (1) | CN114364681A (https=) |
| WO (1) | WO2020236636A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62017B1 (sr) | 2014-09-17 | 2021-07-30 | Celgene Car Llc | Mk2 inhibitori i njihova upotreba |
| WO2018170200A1 (en) | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Heteroaryl compounds useful as mk2 inhibitors |
| WO2018170203A1 (en) | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Mk2 inhibitors, synthesis thereof, and intermediates thereto |
| US10882867B2 (en) | 2017-03-16 | 2021-01-05 | Celgene Car Llc | Forms and compositions of a MK2 inhibitor |
| KR20230044446A (ko) * | 2020-07-24 | 2023-04-04 | 브리스톨-마이어스 스큅 컴퍼니 | 급성 호흡기 장애의 치료 방법 |
| CN116670142A (zh) | 2021-02-01 | 2023-08-29 | 细胞基因公司 | Mk2抑制剂、其合成和其中间体 |
| EP4464694A4 (en) | 2022-01-14 | 2026-04-01 | Shanghai Hansoh Biomedical Co Ltd | POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE |
| CN116643046B (zh) * | 2023-05-30 | 2025-09-12 | 南昌市高新区人民医院(南昌大学第一附属医院高新医院) | Mk2在癌症恶病质肌肉萎缩中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004009776A2 (en) * | 2002-07-19 | 2004-01-29 | Abbott Biotechnology Ltd. | TREATMENT OF TNFα RELATED DISORDERS |
| GB0520164D0 (en) * | 2005-10-04 | 2005-11-09 | Novartis Ag | Organic compounds |
| JP2014088342A (ja) * | 2012-10-30 | 2014-05-15 | Kowa Company Ltd | ベンゾオキサジアゾール誘導体を有効成分とするｍｋ２阻害剤 |
| KR20170033358A (ko) * | 2014-08-07 | 2017-03-24 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 키나아제 저해제의 신규한 제제 |
| US20170281642A1 (en) * | 2014-08-28 | 2017-10-05 | Oncoethix Gmbh | Methods of treating acute myeloid leukemia or acute lymphoid leukemia using pharmaceutical compositions containing thienotriazolodiazepine compounds |
| RS62017B1 (sr) * | 2014-09-17 | 2021-07-30 | Celgene Car Llc | Mk2 inhibitori i njihova upotreba |
| US11098057B2 (en) * | 2017-03-16 | 2021-08-24 | Celgene Car Llc | 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof |
| WO2018170200A1 (en) * | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Heteroaryl compounds useful as mk2 inhibitors |
| WO2018170203A1 (en) * | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Mk2 inhibitors, synthesis thereof, and intermediates thereto |
| US10882867B2 (en) * | 2017-03-16 | 2021-01-05 | Celgene Car Llc | Forms and compositions of a MK2 inhibitor |
-
2020
- 2020-05-15 WO PCT/US2020/033232 patent/WO2020236636A1/en not_active Ceased
- 2020-05-15 EP EP20810459.6A patent/EP3969456A4/en not_active Withdrawn
- 2020-05-15 CN CN202080044746.6A patent/CN114364681A/zh active Pending
- 2020-05-15 JP JP2021568537A patent/JP2022533368A/ja active Pending
- 2020-05-15 US US17/611,594 patent/US20220251105A1/en not_active Abandoned
- 2020-05-15 KR KR1020217041270A patent/KR20220041042A/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022533368A5 (https=) | ||
| EP1755561B1 (en) | Multi-layer tablet comprising non-steroidal anti-inflammatory drugs decongestants and non-sedating antihistamines | |
| JP2023002662A5 (https=) | ||
| JP2025186241A5 (https=) | ||
| JP2021519288A5 (https=) | ||
| JP2005515966A5 (https=) | ||
| CN107260695A (zh) | 硝唑尼特的控制释放药物剂型 | |
| JP2018504398A5 (https=) | ||
| JP2021504384A5 (https=) | ||
| JP2022535893A5 (https=) | ||
| JP2022554276A5 (https=) | ||
| CN105338970B (zh) | 包含他达拉非和坦洛新的药物胶囊复合制剂 | |
| JP2024507810A5 (https=) | ||
| JP2023500032A5 (https=) | ||
| JP2024502446A5 (https=) | ||
| JPS6241646B2 (https=) | ||
| JP2005528429A (ja) | 活性成分の徐放性を有するオクスカルバゼピン含有薬学的組成物 | |
| JP2022500485A5 (https=) | ||
| JP2022535894A5 (https=) | ||
| JP2022540348A5 (https=) | ||
| JP2023510965A5 (https=) | ||
| JP2022177119A5 (https=) | ||
| JP2008533022A5 (https=) | ||
| US20240148693A1 (en) | Composition, preparation method therefor, and use thereof | |
| CZ132698A3 (cs) | Farmaceutický přípravek pro ošetřování poruch autoimunity |